319 related articles for article (PubMed ID: 6810288)
21. [Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study].
Yoshiyama T; Ogata H; Ito K; Aono A; Wada M
Kekkaku; 2007 Feb; 82(2):95-101. PubMed ID: 17373318
[TBL] [Abstract][Full Text] [Related]
22. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model.
Pandey R; Khuller GK
J Antimicrob Chemother; 2004 Jul; 54(1):266-8. PubMed ID: 15128731
[TBL] [Abstract][Full Text] [Related]
23. Study on Mycobacterium tuberculosis: the primary drug resistance pattern.
Siddique MA; Rahman KM; Muazzam N; Hossain T; Islam KM; Rahman MA; Chowdhury FA; Ali CM
Bangladesh Med Res Counc Bull; 1995 Apr; 21(1):18-23. PubMed ID: 7575339
[TBL] [Abstract][Full Text] [Related]
24. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
Almeida D; Nuermberger E; Tasneen R; Rosenthal I; Tyagi S; Williams K; Peloquin C; Grosset J
Antimicrob Agents Chemother; 2009 Oct; 53(10):4178-84. PubMed ID: 19620331
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.
Lounis N; Bentoucha A; Truffot-Pernot C; Ji B; O'Brien RJ; Vernon A; Roscigno G; Grosset J
Antimicrob Agents Chemother; 2001 Dec; 45(12):3482-6. PubMed ID: 11709328
[TBL] [Abstract][Full Text] [Related]
26. Rifampicin mono-resistant Mycobacterium tuberculosis in Bujumbura, Burundi: results of a drug resistance survey.
Sanders M; Van Deun A; Ntakirutimana D; Masabo JP; Rukundo J; Rigouts L; Fissette K; Portaelst F
Int J Tuberc Lung Dis; 2006 Feb; 10(2):178-83. PubMed ID: 16499257
[TBL] [Abstract][Full Text] [Related]
27. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.
Ibrahim M; Andries K; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V; Veziris N
Antimicrob Agents Chemother; 2007 Mar; 51(3):1011-5. PubMed ID: 17178794
[TBL] [Abstract][Full Text] [Related]
28. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.
Lounis N; Veziris N; Chauffour A; Truffot-Pernot C; Andries K; Jarlier V
Antimicrob Agents Chemother; 2006 Nov; 50(11):3543-7. PubMed ID: 16954317
[TBL] [Abstract][Full Text] [Related]
29. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.
Su WJ; Perng RP
Int J Tuberc Lung Dis; 2002 Nov; 6(11):1029-32. PubMed ID: 12475151
[TBL] [Abstract][Full Text] [Related]
30. [Short-term chemotherapy of tuberculosis in children].
Hussein A
Pneumologie; 1990 Jan; 44(1):24-31. PubMed ID: 2408034
[TBL] [Abstract][Full Text] [Related]
31. Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice.
Dutta NK; Mazumdar K; Dastidar SG; Park JH
Int J Antimicrob Agents; 2007 Oct; 30(4):336-40. PubMed ID: 17644321
[TBL] [Abstract][Full Text] [Related]
32. Penetration of isoniazid, rifampicin and pyrazinamide in tuberculous pleural effusion and psoas abscess.
Jutte PC; Rutgers SR; Van Altena R; Uges DR; Van Horn JR
Int J Tuberc Lung Dis; 2004 Nov; 8(11):1368-72. PubMed ID: 15581207
[TBL] [Abstract][Full Text] [Related]
33. Surveillance of Mycobacterium tuberculosis drug resistance in France, 1995-1997. AZAY Mycobacteria Study Group.
Robert J; Trystram D; Truffot-Pernot C; Carbonnelle B; Grosset J
Int J Tuberc Lung Dis; 2000 Jul; 4(7):665-72. PubMed ID: 10907770
[TBL] [Abstract][Full Text] [Related]
34. Isoniazid- and rifampin-resistant tuberculosis in San Diego County, California, United States, 1993-2002.
LoBue PA; Moser KS
Int J Tuberc Lung Dis; 2005 May; 9(5):501-6. PubMed ID: 15875920
[TBL] [Abstract][Full Text] [Related]
35. The clearance of theophylline is increased during the initial period of tuberculosis treatment.
Ahn HC; Lee YC
Int J Tuberc Lung Dis; 2003 Jun; 7(6):587-91. PubMed ID: 12797703
[TBL] [Abstract][Full Text] [Related]
36. Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model.
Byrne ST; Denkin SM; Gu P; Nuermberger E; Zhang Y
J Med Microbiol; 2007 Aug; 56(Pt 8):1047-1051. PubMed ID: 17644711
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.
Hemanth Kumar AK; Kannan T; Chandrasekaran V; Sudha V; Vijayakumar A; Ramesh K; Lavanya J; Swaminathan S; Ramachandran G
Int J Tuberc Lung Dis; 2016 Sep; 20(9):1236-41. PubMed ID: 27510252
[TBL] [Abstract][Full Text] [Related]
38. [Agranulocytosis due to anti-tuberculosis drugs including isoniazid (INH) and rifampicin (RFP)--a report of four cases and review of the literature].
Shishido Y; Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Komatsu H; Yotsumoto H
Kekkaku; 2003 Nov; 78(11):683-9. PubMed ID: 14672045
[TBL] [Abstract][Full Text] [Related]
39. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.
Kumar AK; Chandrasekaran V; Kannan T; Murali AL; Lavanya J; Sudha V; Swaminathan S; Ramachandran G
Eur J Clin Pharmacol; 2017 Jan; 73(1):65-70. PubMed ID: 27651240
[TBL] [Abstract][Full Text] [Related]
40. Pattern of mycobacterial resistance to four anti-tuberculosis drugs in pulmonary tuberculosis patients in the state of Qatar after the implementation of DOTS and a limited expatriate screening programme.
Al-Marri MR
Int J Tuberc Lung Dis; 2001 Dec; 5(12):1116-21. PubMed ID: 11769769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
